<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Yan F</submitter><funding>NCI NIH HHS</funding><pagination>536-549</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8380754</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>165(4)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>Pathologic extranodal extension (ENE) is an important adverse feature for human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), but the prognostic significance of microscopic ENE (ENE&lt;sub>mi&lt;/sub>) and role of adjuvant concurrent chemoradiation (CRT) for ENE&lt;sub>mi&lt;/sub> remain unclear. This study evaluates (1) the prognostic significance of ENE&lt;sub>mi&lt;/sub> in HPV-negative HNSCC and (2) whether adjuvant CRT is associated with improved overall survival (OS) for these patients.&lt;h4>Study design&lt;/h4>Retrospective cohort study.&lt;h4>Setting&lt;/h4>Commission on Cancer (CoC)-accredited facilities.&lt;h4>Methods&lt;/h4>This retrospective cohort study included patients in the National Cancer Database from 2009 to 2015 with pathologic node-positive (pN+) HPV-negative HNSCC with either pathologic ENE&lt;sub>mi&lt;/sub> or no ENE who had undergone margin-negative surgery. The association of ENE&lt;sub>mi&lt;/sub> with OS was evaluated using Cox proportional hazard analyses. Analyses were repeated in patients with ENE&lt;sub>mi&lt;/sub> receiving adjuvant therapy to evaluate the association of adjuvant CRT with OS.&lt;h4>Results&lt;/h4>We included 5483 patients with pN+ HPV-negative HNSCC, of whom 24% had ENE&lt;sub>mi&lt;/sub>. On multivariable analysis, ENE&lt;sub>mi&lt;/sub> was associated with decreased OS relative to no ENE (adjusted hazard ratio [aHR], 1.43; 95% CI, 1.28-1.59). Among patients with ENE&lt;sub>mi&lt;/sub> who received ≥60 Gy of adjuvant radiation therapy (RT) (n = 617), adjuvant CRT was not associated with improved OS relative to RT (aHR, 0.91; 95% CI, 0.66-1.27).&lt;h4>Conclusion&lt;/h4>For patients with HPV-negative HNSCC, pN+ with ENE&lt;sub>mi&lt;/sub> is associated with worse OS than pN+ without ENE. However, for patients with ENE&lt;sub>mi&lt;/sub>, concurrent CRT is not associated with improved OS relative to RT. The optimal adjuvant paradigm for ENE&lt;sub>mi&lt;/sub> requires additional investigation.</pubmed_abstract><journal>Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery</journal><pubmed_title>Microscopic Extranodal Extension in HPV-Negative Head and Neck Cancer and the Role of Adjuvant Chemoradiation.</pubmed_title><pmcid>PMC8380754</pmcid><funding_grant_id>P30 CA138313</funding_grant_id><pubmed_authors>Richardson MS</pubmed_authors><pubmed_authors>Li H</pubmed_authors><pubmed_authors>Graboyes EM</pubmed_authors><pubmed_authors>Day TA</pubmed_authors><pubmed_authors>Pipkorn P</pubmed_authors><pubmed_authors>Kaczmar JM</pubmed_authors><pubmed_authors>de Almeida JR</pubmed_authors><pubmed_authors>Sharma AK</pubmed_authors><pubmed_authors>Neskey DM</pubmed_authors><pubmed_authors>Yan F</pubmed_authors><pubmed_authors>Zenga J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Microscopic Extranodal Extension in HPV-Negative Head and Neck Cancer and the Role of Adjuvant Chemoradiation.</name><description>&lt;h4>Objective&lt;/h4>Pathologic extranodal extension (ENE) is an important adverse feature for human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), but the prognostic significance of microscopic ENE (ENE&lt;sub>mi&lt;/sub>) and role of adjuvant concurrent chemoradiation (CRT) for ENE&lt;sub>mi&lt;/sub> remain unclear. This study evaluates (1) the prognostic significance of ENE&lt;sub>mi&lt;/sub> in HPV-negative HNSCC and (2) whether adjuvant CRT is associated with improved overall survival (OS) for these patients.&lt;h4>Study design&lt;/h4>Retrospective cohort study.&lt;h4>Setting&lt;/h4>Commission on Cancer (CoC)-accredited facilities.&lt;h4>Methods&lt;/h4>This retrospective cohort study included patients in the National Cancer Database from 2009 to 2015 with pathologic node-positive (pN+) HPV-negative HNSCC with either pathologic ENE&lt;sub>mi&lt;/sub> or no ENE who had undergone margin-negative surgery. The association of ENE&lt;sub>mi&lt;/sub> with OS was evaluated using Cox proportional hazard analyses. Analyses were repeated in patients with ENE&lt;sub>mi&lt;/sub> receiving adjuvant therapy to evaluate the association of adjuvant CRT with OS.&lt;h4>Results&lt;/h4>We included 5483 patients with pN+ HPV-negative HNSCC, of whom 24% had ENE&lt;sub>mi&lt;/sub>. On multivariable analysis, ENE&lt;sub>mi&lt;/sub> was associated with decreased OS relative to no ENE (adjusted hazard ratio [aHR], 1.43; 95% CI, 1.28-1.59). Among patients with ENE&lt;sub>mi&lt;/sub> who received ≥60 Gy of adjuvant radiation therapy (RT) (n = 617), adjuvant CRT was not associated with improved OS relative to RT (aHR, 0.91; 95% CI, 0.66-1.27).&lt;h4>Conclusion&lt;/h4>For patients with HPV-negative HNSCC, pN+ with ENE&lt;sub>mi&lt;/sub> is associated with worse OS than pN+ without ENE. However, for patients with ENE&lt;sub>mi&lt;/sub>, concurrent CRT is not associated with improved OS relative to RT. The optimal adjuvant paradigm for ENE&lt;sub>mi&lt;/sub> requires additional investigation.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Oct</publication><modification>2025-04-04T12:04:29.073Z</modification><creation>2025-04-04T12:04:29.073Z</creation></dates><accession>S-EPMC8380754</accession><cross_references><pubmed>33618570</pubmed><doi>10.1177/0194599821989637</doi></cross_references></HashMap>